Hugh Gannon

1.3k citations

14 papers · 474 indexed · h-index 9

Aging
Cancer Research
Oncology
- Cancer-related Molecular Pathways 5
- CAR-T cell therapy research 2
- PARP inhibition in cancer therapy 2
Molecular Biology
- CRISPR and Genetic Engineering 6
- DNA Repair Mechanisms 6
- Epigenetics and DNA Methylation 2
Immunology
Biotechnology
- Cancer Research and Treatments 3
Cardiology and Cardiovascular Medicine
- Viral Infections and Immunology Research 1

Co-authors: Stephen N. Jones Bruce A. Woda Lawrence A. Donehower Stephen Lyle Francisca Vázquez William C. Hahn Matthew Meyerson Aviad Tsherniak
Cited by: Aging Cancer Research Oncology
Journals: Proceedings of the National Academy of Sciences (1 paper)Nature Communications (1 paper)SHILAP Revista de lepidopterología (1 paper)
Partner nations: United States Switzerland Israel

In The Last Decade

Hugh Gannon

14 papers receiving 469 citations

Peers

Countries citing papers authored by Hugh Gannon

Since Specialization

Citations

This map shows the geographic impact of Hugh Gannon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Gannon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Gannon more than expected).

Fields of papers citing papers by Hugh Gannon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugh Gannon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Gannon. The network helps show where Hugh Gannon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hugh Gannon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hugh Gannon Line = papers co-authored together Hugh Gannon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Abstract 1581: KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers Cancer Research ·Erica R. Tobin,Pamela Sullivan,Morgan Murray,Hugh Gannon,Anne E. Dodson,Sol Shenker,Frank Stegmeier,Andrew A. Wylie,Louise Cadzow	2023	2
2	Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death Cancer Research ·Sumeet Nayak,Pamela Sullivan,Yuji Mishina,Anne E. Dodson,Pei-Lun Kao,Hugh Gannon,Chris T. Middleton,Sol Shenker,Morgan Murray,Michael R. Schlabach,Frank Stegmeier,Erica R. Tobin,Louise Cadzow,Andrew A. Wylie	2023	1
3	255 ExPRESS^TM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTIL^TM product Regular and Young Investigator Award Abstracts ·Sharon Lin,Leila J. Williams,Mitali Ghose,Hugh Gannon,Conor Calnan,Angelina Pizzo,Pei-Lun Kao,Mallory Brady,Katri Sofjan,Anne E. Dodson,Sol Shenker,Michael R. Schlabach,Fiona A. Sharp,Frank Stegmeier,Micah J. Benson,Karrie Wong	2022	1
4	Abstract 1337: Functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drugs Cancer Research ·Sol Shenker,Hugh Gannon,Alyssa Carlson,Paula Grasberger,Pamela Sullivan,Chris T. Middleton,Anne E. Dodson,Caroline Bullock,Michael H. McGuire,Erica R. Tobin,Kerstin W. Sinkevicius,Mike Schlabach,Frank Stegmeier,Louise Cadzow,Andrew A. Wylie	2021	7
5	186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1 SHILAP Revista de lepidopterología ·Karrie Wong,Sharon Lin,Christopher Wrocklage,Katri Sofjan,Leila J. Williams,Mallory Brady,Nicholas Colletti,Noah Tubo,Hugh Gannon,Robert A. LaMothe,Tianlei Xu,Tracy VandenBerg,Sol Shenker,Caroline Dugopolski,Frank Stegmeier,Louise Cadzow,Michael R. Schlabach,Micah J. Benson	2021	1
6	Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells Nature Communications ·Hugh Gannon,Tao Zou,Michael K. Kießling,Galen F. Gao,Diana Cai,Peter S. Choi,Alexandru P. Ivan,Ilana Buchumenski,Ashton C. Berger,Jonathan T. Goldstein,Andrew D. Cherniack,Francisca Vázquez,Aviad Tsherniak,Erez Y. Levanon,William C. Hahn,Matthew Meyerson	2018	159
7	Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis Cell Reports ·Michael I. Carr,Justine E. Roderick,Hugh Gannon,Michelle A. Kelliher,Stephen N. Jones	2016	24
8	Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy Molecular Cancer Research ·Hugh Gannon,Nathan O. Kaplan,Aviad Tsherniak,Francisca Vázquez,Barbara A. Weir,William C. Hahn,Matthew Meyerson	2015	19
9	ATM Phosphorylation of Mdm2 Ser394 Regulates the Amplitude and Duration of the DNA Damage Response in Mice Cancer Cell ·Hugh Gannon,Bruce A. Woda,Stephen N. Jones	2012	69
10	Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis Genes & Cancer ·Hugh Gannon,Stephen N. Jones	2012	19
11	Mdm2–p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin Developmental Biology ·Hugh Gannon,Lawrence A. Donehower,Stephen Lyle,Stephen N. Jones	2011	71
12	Aerobic Glycolysis Suppresses p53 Activity to Provide Selective Protection from Apoptosis upon Loss of Growth Signals or Inhibition of BCR-Abl Cancer Research ·Emily F. Mason,Yuxing Zhao,Pankuri Goraksha-Hicks,Jonathan L. Coloff,Hugh Gannon,Stephen N. Jones,Jeffrey C. Rathmell	2010	39
13	Inhibitor of growth-4 promotes IκB promoter activation to suppress NF-κB signaling and innate immunity Proceedings of the National Academy of Sciences ·Andrew H. Coles,Hugh Gannon,Anna Cerny,Evelyn A. Kurt‐Jones,Stephen N. Jones	2010	49
14	Phosphorylation of p53 Serine 18 Upregulates Apoptosis to Suppress Myc-Induced Tumorigenesis Molecular Cancer Research ·Hayla K. Sluss,Hugh Gannon,Andrew H. Coles,Qichang Shen,Christine M. Eischen,Stephen N. Jones	2010	13

About Hugh Gannon

Hugh Gannon is a scholar working on Biotechnology, Oncology and Molecular Biology, having authored 14 papers that have together received 474 indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (6 papers), DNA Repair Mechanisms (6 papers), Cancer-related Molecular Pathways (5 papers), Cancer Research and Treatments (3 papers), Epigenetics and DNA Methylation (2 papers), CAR-T cell therapy research (2 papers), PARP inhibition in cancer therapy (2 papers) and Viral Infections and Immunology Research (1 paper). The work is most often cited by research in Aging (11 citations), Cancer Research (92 citations) and Oncology (163 citations). Hugh Gannon has collaborated with scholars based in United States, Switzerland and Israel. Frequent co-authors include Stephen N. Jones, Bruce A. Woda, Lawrence A. Donehower, Stephen Lyle, Francisca Vázquez, William C. Hahn, Matthew Meyerson, Aviad Tsherniak, Andrew H. Coles and Galen F. Gao. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact